Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:
- at least 18 years old
- diagnosis of heart failure
- hospitalization or urgent/unplanned visit with a primary diagnosis of decompensated heart failure which required intravenous diuretic treatment, within the last 9 months prior to starting the study
- left ventricular ejection fraction (LVEF) greater than 40% documented by echocardiogram in the past year
- contact study staff for additional requirements

Exclusion Criteria:
- myocardial infarction, stroke, unstable angina pectoris, transient ischemic attack, or heart failure hospitalization within 30 days
- planned cardiac procedures (ablation, revascularization - primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD etc.)
- women who are pregnant, breast-feeding or planning to get pregnant during the study period
- contact study staff for additional exclusion criteria

Conditions & Interventions

Conditions:
Heart & Vascular

Keywords:
Heart Failure

Description:
We are looking at a new drug called 'ziltivekimab' to see if it can be used to treat people living with heart failure and inflammation. People will get either ziltivekimab or a placebo (inactive dummy drug). The study drug is an injection given into the fold of the skin on the stomach, thigh or upper arm once every month. People will take the study drug for up to 4 years.

Study Contact: Alexandra Clute - aclute@healtheast.org
Principal Investigator: Les Forgosh
IRB Number: SITE00001919

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.